Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA

24Citations
Citations of this article
47Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Aim: To evaluate treatment patterns of diffuse large B-cell lymphoma (DLBCL). Patients & methods: First-line and relapsed/refractory treatment patterns and survival outcomes following first-line therapy in adult patients newly diagnosed with DLBCL were evaluated. Results: A total of 1436 DLBCL patients initiated treatment and mainly received a combination regimen versus monotherapy (92.1 vs 7.9%). Patients who received monotherapy were older with more comorbidities and had shorter progression-free survival than patients receiving combination therapy (median: 31.3 vs 55.8 months). In the second-line setting (n = 164), rituximab-based combination regimens were most common; 25% underwent stem cell transplantation, and were younger with fewer comorbidities. Conclusion: These results illustrate the need for new treatment options for patients unable to tolerate initial combination therapy and transplant-ineligible patients who require salvage therapy.

References Powered by Scopus

Cancer statistics, 2016

23615Citations
N/AReaders
Get full text

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1838Citations
N/AReaders
Get full text

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1375Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review

25Citations
N/AReaders
Get full text

Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S

16Citations
N/AReaders
Get full text

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Morrison, V. A., Shou, Y., Bell, J. A., Hamilton, L., Ogbonnaya, A., Raju, A., … Galaznik, A. (2019). Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncology, 15(9), 1021–1034. https://doi.org/10.2217/fon-2018-0788

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

48%

Researcher 8

38%

Professor / Associate Prof. 3

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

65%

Biochemistry, Genetics and Molecular Bi... 4

20%

Nursing and Health Professions 2

10%

Pharmacology, Toxicology and Pharmaceut... 1

5%

Article Metrics

Tooltip
Mentions
News Mentions: 2

Save time finding and organizing research with Mendeley

Sign up for free